Armata Pharmaceuticals (ARMP) News Today $1.44 +0.09 (+6.85%) Closing price 05/2/2025 04:10 PM EasternExtended Trading$1.45 +0.01 (+0.90%) As of 05/2/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Armata Pharmaceuticals secures additional DoD fundingMay 3 at 5:34 PM | uk.investing.comArmata Pharmaceuticals (ARMP) Expected to Announce Earnings on TuesdayArmata Pharmaceuticals (NYSEAMERICAN:ARMP) will be releasing earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-armata-pharmaceuticals-inc-stock/)May 1 at 7:27 AM | marketbeat.comArmata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02May 1 at 7:00 AM | prnewswire.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3%Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 7,700 shares, an increase of 28.3% from the February 28th total of 6,000 shares. Currently, 0.1% of the company's shares are short sold. Based on an average daily volume of 12,600 shares, the days-to-cover ratio is presently 0.6 days.April 1, 2025 | marketbeat.comHC Wainwright Comments on Armata Pharmaceuticals Q1 EarningsArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Armata Pharmaceuticals in a report issued on Friday, March 21st. HC Wainwright analyst J. Pantginis expects that the companyMarch 24, 2025 | marketbeat.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate UpdateMarch 21, 2025 | finanznachrichten.deArmata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last yearMarch 21, 2025 | markets.businessinsider.comArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate UpdateMarch 20, 2025 | prnewswire.comArmata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on ThursdayArmata Pharmaceuticals (NYSEAMERICAN:ARMP) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comArmata Pharmaceuticals Announces $10 Million Secured Credit Agreement with InnovivaMarch 12, 2025 | prnewswire.comArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy SummitMarch 11, 2025 | prnewswire.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest UpdateArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 7,100 shares, a drop of 61.8% from the January 31st total of 18,600 shares. Based on an average daily volume of 11,000 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the company's stock are short sold.March 1, 2025 | marketbeat.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 7.5%Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 18,600 shares, a growth of 7.5% from the January 15th total of 17,300 shares. Currently, 0.2% of the company's shares are sold short. Based on an average daily volume of 11,200 shares, the short-interest ratio is currently 1.7 days.February 18, 2025 | marketbeat.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 203.3%Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 18,500 shares, an increase of 203.3% from the December 15th total of 6,100 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily trading volume, of 10,700 shares, the short-interest ratio is currently 1.7 days.January 14, 2025 | marketbeat.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 125.9% in DecemberArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 6,100 shares, an increase of 125.9% from the November 30th total of 2,700 shares. Based on an average daily trading volume, of 9,000 shares, the short-interest ratio is presently 0.7 days. Approximately 0.1% of the company's stock are short sold.December 27, 2024 | marketbeat.comPromising Phase 2 Results for AP-PA02 Boost Armata Pharmaceuticals’ Investment AppealDecember 22, 2024 | markets.businessinsider.comArmata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 studyDecember 20, 2024 | finance.yahoo.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a research report on Thursday.December 19, 2024 | marketbeat.comArmata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionDecember 19, 2024 | prnewswire.comSuparna Mishra SarkarDecember 16, 2024 | latimes.comArmata Pharmaceuticals Announces CMO Departure AgreementDecember 5, 2024 | markets.businessinsider.comArmata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual MeetingNovember 19, 2024 | prnewswire.comArmata Pharmaceuticals FY2024 EPS Raised by HC WainwrightArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of Armata Pharmaceuticals in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasNovember 18, 2024 | marketbeat.comArmata Pharmaceuticals Extends Credit Agreement and CMO DepartsNovember 15, 2024 | markets.businessinsider.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate UpdateNovember 15, 2024 | finanznachrichten.deArmata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate UpdateNovember 13, 2024 | prnewswire.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a report on Tuesday.November 12, 2024 | marketbeat.comArmata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus BacteremiaNovember 12, 2024 | prnewswire.comArmata Pharmaceuticals Announces Structural Biology PublicationOctober 30, 2024 | prnewswire.comArmata Pharmaceuticals (AMEX:ARMP) Stock Quotes, Forecast and News SummaryOctober 18, 2024 | benzinga.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Decline in Short InterestArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 3,400 shares, a decrease of 35.8% from the September 15th total of 5,300 shares. Based on an average daily volume of 8,100 shares, the short-interest ratio is presently 0.4 days. Currently, 0.0% of the company's stock are short sold.October 12, 2024 | marketbeat.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.2% - Time to Sell?Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 2.2% - Here's What HappenedOctober 10, 2024 | marketbeat.comRakovina Therapeutics Inc. (RKV.V) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Increase in Short InterestArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 7,000 shares, an increase of 11.1% from the August 15th total of 6,300 shares. Based on an average daily volume of 9,300 shares, the short-interest ratio is presently 0.8 days. Approximately 0.1% of the company's shares are sold short.September 18, 2024 | marketbeat.comARMP Armata Pharmaceuticals, Inc.September 9, 2024 | seekingalpha.comArmata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | prnewswire.comTG1M.SG,0P00015OC5,0 (TG1M.SG)September 3, 2024 | ca.finance.yahoo.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 133.3% in AugustArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 6,300 shares, a growth of 133.3% from the July 31st total of 2,700 shares. Based on an average daily volume of 10,400 shares, the short-interest ratio is presently 0.6 days. Currently, 0.1% of the company's stock are sold short.August 29, 2024 | marketbeat.comArmata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research SymposiumAugust 26, 2024 | prnewswire.comSilexion Therapeutics CorpAugust 24, 2024 | money.usnews.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Drops By 12.9%Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 2,700 shares, a decline of 12.9% from the July 15th total of 3,100 shares. Approximately 0.0% of the company's shares are sold short. Based on an average daily volume of 11,700 shares, the short-interest ratio is presently 0.2 days.August 18, 2024 | marketbeat.comArmata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial OfficerAugust 15, 2024 | prnewswire.comBuy Rating Justified by Armata Pharmaceuticals’ Advancements in Bacteriophage Therapeutics and Strategic PartnershipsAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Positive Earnings and Promising Clinical ProgressAugust 15, 2024 | markets.businessinsider.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate UpdateAugust 14, 2024 | finanznachrichten.deArmata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate UpdateAugust 13, 2024 | prnewswire.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 2.8%Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 2.8%August 2, 2024 | marketbeat.comArmata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02July 30, 2024 | prnewswire.comInnoviva’s (INVA) Stock Is Thriving With Strategic Investments Pay-OffJuly 28, 2024 | msn.comArmata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa InfectionJuly 11, 2024 | prnewswire.com Get Armata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. Email Address ARMP Media Mentions By Week ARMP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARMP News Sentiment▼-0.090.65▲Average Medical News Sentiment ARMP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARMP Articles This Week▼31▲ARMP Articles Average Week Get Armata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Annexon News Today INmune Bio News Today Canopy Growth News Today Y-mAbs Therapeutics News Today Voyager Therapeutics News Today Gossamer Bio News Today Kodiak Sciences News Today TuHURA Biosciences News Today DBV Technologies News Today Esperion Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:ARMP) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARMP Stock Free ARMP Stock Alerts